Send to

Choose Destination
Avicenna J Med. 2019 Jan-Mar;9(1):32-34. doi: 10.4103/ajm.AJM_171_17.

Possible acute rejection associated with the use of the new anti-hepatitis C virus medications.

Author information

Department of Internal Medicine, Tawam Hospital, Al-Ain, United Arab Emirates.
Division of Nephrology, Tawam Hospital, Al-Ain, United Arab Emirates.
Department of Pathology, College of Medicine and Health Sciences, UAE University, Al-Ain, United Arab Emirates.


Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new direct-acting antiviral agents gave big hopes to both clinicians and patients that they can overcome this challenge without major side effects. Studies recently have supported this claim; however, they are still few, limited, and may give false hopes. In the following case report, we present a case, supported by histological evidence about a possible acute rejection of kidney transplant after treatment with these new medications. This case is limited by the absence of donor-specific antibodies. This report is aimed to increase awareness about the urgent need for further studies.


Acute rejection; anti-hepatitis C virus medication; daclatasvir; direct-acting antiviral agents; kidney transplant; sofosbuvir

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center